Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer

Thyroid

Volumn 21, Issue 7, 2011, Pages 691-692

  Pacini, Furio ^a   Sabra, Mona M ^b   Tuttle, R Michael ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; RADIOACTIVE IODINE; THYROGLOBULIN;

CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; EDITORIAL; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THYROGLOBULIN BLOOD LEVEL; THYROGLOBULINEMIA; THYROID DISEASE; THYROIDECTOMY; TUMOR VOLUME;

FEMALE; HUMANS; MALE; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN;

EID: 79959820608     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.2107.ed1     Document Type: Editorial

References (7)

1. Tuttle RM, Leboeuf R, Shaha A 2008 Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol 97: 712-716. (Pubitemid 351812974)
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
3. Castagna MG, Belardini V, Cipri C, Theodouropulus A, Pacini F 2010 The clinical impact of an "ongoing risk stratification" in patients with differentiated thyroid carcinoma. Abstract, International Thyroid Congress, Paris.
4. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
5. Miyauchi A,Kudo T,MiyaA,KobayashiK, ItoY, Shimoyamatedori C, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Tomoda C, Inoue H, Yabuta T, Masuoka H 2011 Prognostic impact of serum thyroglobulin doubling-time under TSH suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21:707-716.
6. Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y 1984 Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461-466. (Pubitemid 14139883)
7. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097. (Pubitemid 32848518)